Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

Core Insights - Supernus Pharmaceuticals, Inc. is set to present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025, at 3:20 p.m. ET, with Jack A. Khattar, the President and CEO, leading the presentation [1] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [3] - The company has a diverse neuroscience portfolio that includes approved treatments for various conditions such as ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4] Conference Details - Investors interested in meeting with company management during the conference can contact the Bank of America conference coordinator [2] - A live audio webcast of the presentation will be available, and an archived replay will be accessible for 60 days following the conference on the company's website [2]